Goldsmith Mark A's Form 4 filing
Revolution Medicines, Inc. (RVMD) · filed Sep 6, 2023
- Accession no.
- 0001610717-23-000261
- Filed
- Sep 6, 2023
- Trade date
- Sep 1, 2023
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.40M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Goldsmith Mark ACIK 0001246842 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2023 | Common Stock | MOption exerciseAcquired | +17,993 | $0.54 | +$9,716.22 | 375,379 | Direct | |
| Sep 1, 2023 | Common Stock | MOption exerciseAcquired | +12,007 | $1.12 | +$13,447.84 | 387,386 | Direct | |
| Sep 1, 2023 | Common Stock | SSaleDisposed | −30,000 | $35.05F4 | −$1,051,500 | 357,386 | Direct | |
| Sep 1, 2023 | Common Stock | SSaleDisposed | −5,000 | $35.04F6 | −$175,200 | 35,424 | Indirect | |
| Sep 1, 2023 | Common Stock | SSaleDisposed | −5,000 | $35.04F9 | −$175,200 | 35,424 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2023 | Common Stock | MOption exerciseDisposed | −17,993 | $0.00 | $0 | 205,503 | Direct | |
| Sep 1, 2023 | Common Stock | MOption exerciseDisposed | −12,007 | $0.00 | $0 | 46,479 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
This transaction was executed in multiple trades at prices ranging from $35.00 to $35.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F6
This transaction was executed in multiple trades at prices ranging from $35.00 to $35.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F9
This transaction was executed in multiple trades at prices ranging from $35.00 to $35.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
President and Chief Executive Officer